Societal CDMO, Inc. is a bi-coastal CDMO with capabilities spanning pre-investigational new drug (IND) development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a focus on small molecules. The company is headquartered in Exton, Pennsylvania and currently employs 275 full-time employees. The company went IPO on 2014-03-07. The firm is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus on the area of small molecules. The company is involved in CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company’s products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR, Donnatal liquids and tablets and Scot-Tussin cough and cold liquids. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms and facilities to handle highly potent compounds and controlled substances.

Industry: Pharmaceutical Preparations Peers: LeonaBio Inc Relmada Therapeutics Inc Eton Pharmaceuticals Inc EyePoint Inc Johnson & Johnson OPIANT PHARMACEUTICALS, INC. Longboard Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. RVL Pharmaceuticals plc